Clinical Trial Update: Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study to assess safety and tolerability of Genz-644282 in patients with solid tumors has been completed, summarizing initial safety data…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Genz-644282

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Solid Tumors | Phase 1 | Status: COMPLETED